Biomarkers such as prothrombin fragment 1+2 and thrombin-antithrombin complexes can be used to assess thrombin activity. These biomarkers help in diagnosing and monitoring thrombotic disorders and the efficacy of anticoagulant therapy. Clinical assessments often involve measuring these biomarkers to tailor treatment plans accordingly.
